GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
GO:003010018 | Esophagus | ESCC | regulation of endocytosis | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
GO:004580718 | Esophagus | ESCC | positive regulation of endocytosis | 69/8552 | 100/18723 | 1.97e-06 | 2.29e-05 | 69 |
GO:000647015 | Oral cavity | OSCC | protein dephosphorylation | 162/7305 | 281/18723 | 1.56e-10 | 4.56e-09 | 162 |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
GO:003010016 | Oral cavity | OSCC | regulation of endocytosis | 121/7305 | 211/18723 | 4.74e-08 | 8.80e-07 | 121 |
GO:004580710 | Oral cavity | OSCC | positive regulation of endocytosis | 59/7305 | 100/18723 | 3.99e-05 | 3.48e-04 | 59 |
GO:1903421 | Oral cavity | OSCC | regulation of synaptic vesicle recycling | 18/7305 | 27/18723 | 3.34e-03 | 1.42e-02 | 18 |
GO:00331733 | Oral cavity | OSCC | calcineurin-NFAT signaling cascade | 26/7305 | 43/18723 | 3.55e-03 | 1.49e-02 | 26 |
GO:00480164 | Oral cavity | OSCC | inositol phosphate-mediated signaling | 30/7305 | 55/18723 | 1.39e-02 | 4.59e-02 | 30 |
GO:000647023 | Oral cavity | EOLP | protein dephosphorylation | 72/2218 | 281/18723 | 1.19e-10 | 1.35e-08 | 72 |
GO:001631114 | Oral cavity | EOLP | dephosphorylation | 85/2218 | 417/18723 | 3.19e-07 | 9.47e-06 | 85 |
GO:003010023 | Oral cavity | EOLP | regulation of endocytosis | 51/2218 | 211/18723 | 4.24e-07 | 1.19e-05 | 51 |
GO:004580724 | Oral cavity | EOLP | positive regulation of endocytosis | 27/2218 | 100/18723 | 2.69e-05 | 3.94e-04 | 27 |
GO:00990035 | Oral cavity | EOLP | vesicle-mediated transport in synapse | 39/2218 | 200/18723 | 1.14e-03 | 8.29e-03 | 39 |
GO:00995044 | Oral cavity | EOLP | synaptic vesicle cycle | 34/2218 | 181/18723 | 4.25e-03 | 2.33e-02 | 34 |
GO:00484885 | Oral cavity | EOLP | synaptic vesicle endocytosis | 15/2218 | 62/18723 | 5.00e-03 | 2.64e-02 | 15 |
GO:01402385 | Oral cavity | EOLP | presynaptic endocytosis | 15/2218 | 62/18723 | 5.00e-03 | 2.64e-02 | 15 |
GO:003010031 | Oral cavity | NEOLP | regulation of endocytosis | 47/2005 | 211/18723 | 7.96e-07 | 2.20e-05 | 47 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0502228 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
hsa0502028 | Oral cavity | OSCC | Prion disease | 181/3704 | 273/8465 | 2.05e-14 | 5.30e-13 | 2.70e-13 | 181 |
hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
hsa0421820 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
hsa0516729 | Oral cavity | OSCC | Kaposi sarcoma-associated herpesvirus infection | 125/3704 | 194/8465 | 3.67e-09 | 3.84e-08 | 1.96e-08 | 125 |
hsa0517027 | Oral cavity | OSCC | Human immunodeficiency virus 1 infection | 133/3704 | 212/8465 | 1.42e-08 | 1.40e-07 | 7.12e-08 | 133 |
hsa0516328 | Oral cavity | OSCC | Human cytomegalovirus infection | 139/3704 | 225/8465 | 2.77e-08 | 2.38e-07 | 1.21e-07 | 139 |
hsa046258 | Oral cavity | OSCC | C-type lectin receptor signaling pathway | 73/3704 | 104/8465 | 3.83e-08 | 3.12e-07 | 1.59e-07 | 73 |
hsa0541730 | Oral cavity | OSCC | Lipid and atherosclerosis | 131/3704 | 215/8465 | 2.20e-07 | 1.45e-06 | 7.37e-07 | 131 |
hsa046606 | Oral cavity | OSCC | T cell receptor signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa051526 | Oral cavity | OSCC | Tuberculosis | 105/3704 | 180/8465 | 5.00e-05 | 2.04e-04 | 1.04e-04 | 105 |
hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
hsa046598 | Oral cavity | OSCC | Th17 cell differentiation | 65/3704 | 108/8465 | 4.02e-04 | 1.25e-03 | 6.35e-04 | 65 |
hsa043806 | Oral cavity | OSCC | Osteoclast differentiation | 73/3704 | 128/8465 | 1.60e-03 | 4.44e-03 | 2.26e-03 | 73 |
hsa04114 | Oral cavity | OSCC | Oocyte meiosis | 74/3704 | 131/8465 | 2.13e-03 | 5.75e-03 | 2.92e-03 | 74 |
hsa04370 | Oral cavity | OSCC | VEGF signaling pathway | 37/3704 | 59/8465 | 2.53e-03 | 6.62e-03 | 3.37e-03 | 37 |
hsa046584 | Oral cavity | OSCC | Th1 and Th2 cell differentiation | 53/3704 | 92/8465 | 5.00e-03 | 1.20e-02 | 6.13e-03 | 53 |
hsa0436014 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa04662 | Oral cavity | OSCC | B cell receptor signaling pathway | 48/3704 | 84/8465 | 9.02e-03 | 2.01e-02 | 1.03e-02 | 48 |
hsa05014112 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP3CC | insertion | Nonsense_Mutation | novel | c.420_421insGCAAATCTAATGAGAAAATAGTGTACTTGTCAC | p.Leu140_Phe141insAlaAsnLeuMetArgLysTerCysThrCysHis | p.L140_F141insANLMRK*CTCH | P48454 | protein_coding | | | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPP3CC | SNV | Missense_Mutation | | c.1466G>A | p.Arg489Gln | p.R489Q | P48454 | protein_coding | deleterious(0.04) | possibly_damaging(0.579) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
PPP3CC | SNV | Missense_Mutation | novel | c.916N>T | p.Asn306Tyr | p.N306Y | P48454 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A8XI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
PPP3CC | SNV | Missense_Mutation | novel | c.356N>C | p.Gly119Ala | p.G119A | P48454 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
PPP3CC | SNV | Missense_Mutation | rs767818391 | c.7N>A | p.Gly3Arg | p.G3R | P48454 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPP3CC | SNV | Missense_Mutation | rs142268010 | c.749N>A | p.Arg250Gln | p.R250Q | P48454 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP3CC | SNV | Missense_Mutation | novel | c.1379C>G | p.Ala460Gly | p.A460G | P48454 | protein_coding | tolerated(0.12) | possibly_damaging(0.611) | TCGA-AY-4070-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fu | PD |
PPP3CC | SNV | Missense_Mutation | novel | c.115N>T | p.Val39Phe | p.V39F | P48454 | protein_coding | tolerated(0.3) | benign(0.001) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
PPP3CC | SNV | Missense_Mutation | novel | c.4N>C | p.Ser2Pro | p.S2P | P48454 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-AG-3602-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PPP3CC | SNV | Missense_Mutation | rs558233561 | c.1483N>A | p.Ala495Thr | p.A495T | P48454 | protein_coding | tolerated(0.52) | benign(0) | TCGA-EI-6510-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |